



**2013: COMBATING CLOSTRIDIUM DIFFICILE**

# Applications for research funding now being invited for **2013**



Astellas is pleased to announce the first Astellas Grant in Anti-infectives Research Award. The aim of the award is to promote innovative research ideas in key areas of infectious diseases. The focus of the grant programme for 2013 is *Clostridium difficile* infection (CDI).

High-quality, scientific research grant applications are now invited from healthcare professionals in a healthcare setting, from Europe, the Middle East and North Africa\*, who have a research proposal which may ultimately lead to important innovations in the field of CDI and advances in knowledge that are likely to make an impact on patient care.

Each single award will be for a maximum of €50,000 and the maximum award fund available for 2013 is €100,000. Cost-effectiveness of the proposed research will be one of the important factors judged during the peer review process.

Deadline for submission is midnight, Central European Time, 31st January, 2013. Only online applications will be considered.

\*Details of eligible countries are available at [www.agar-research.eu](http://www.agar-research.eu)

AGAR award is organised and funded by Astellas Pharma Europe Ltd with review of proposals by an independent panel of judges

 For further information visit [www.agar-research.eu](http://www.agar-research.eu)

